CRISPR Therapeutics AG Aktie News

ZUG, Schweiz und BOSTON, 19. Okt. 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) gab heute bekannt, dass sein Chief Financial Officer, Raju Prasad, Ph.D., das Company verlassen wird, um externe Möglichkeiten zu verfolgen, und A.J.

-Daten in einer Late‑Breaking‑Präsentation auf dem European Society of Cardiology (ESC) Congress 2026 vorgestellt- -Phase‑1a‑Klinikdaten für CTX310® zeigten weiterhin robuste, dosisabhängige Reduktionen des zirkulierenden ANGPTL3 mit einer mittleren Reduktion gegenüber Basiswert von 79 % (maximal 89 %), einer mittleren Reduktion der Triglyceride (TG) von 48 % (maximal 78 %) und einer mittleren ...

ZUG, Switzerland und BOSTON, 03. Aug. 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) berichtete heute über die Finanzergebnisse für das am 30. Juni 2026 endende zweite Quartal.

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Time: 9:55 a.m.

ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT.

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.